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Introduction 
Insect vector-borne protozoan parasites of the order 
Kinetoplastida cause a range of neglected human diseases, 
most notably leishmaniasis, Chagas disease and African 
sleeping sickness. Globally, these diseases lead to greater 
than 100,000 deaths annually, and cause the loss of more 
than 4 million disability-adjusted life years (ie, healthy 
years of life lost as a result of premature death and 
disability) [1]. The mortality and morbidity caused by 
leishmaniasis (both visceral leishmaniasis [VL] and 
cutaneous leishmaniasis [CL]) is only surpassed among 
parasitic diseases by malaria and lymphatic filariasis [2]. 
The kinetoplastid parasites that cause leishmaniasis are 
endemic in tropical and subtropical regions and, therefore, 
disproportionately affect the health and economic viability 
of most of the developing world.  Leishmania spp – the 
causative agents of leishmaniasis – infect more than 12 
million individuals in five continents, and are endemic 
in 88 countries; thus, more than 350 million individuals 
are at risk of infection [1]. Instances of leishmaniasis are 
also not uncommon in certain regions of North America 
and southern Europe. In addition, the spread and severity 
of the disease is exacerbated by its status as a possible 
coinfection in patients with AIDS and the overlap in 
prevalence of HIV and Leishmania [3].
The treatment of leishmaniasis, as well as trypanosomiasis 
(another parasitic disease caused by kinetoplastids), 
is difficult [4,5]. VL, the most serious form of 
leishmaniasis, requires an extended, costly course of 
drug treatment. In addition, Leishmania drug resistance 
has recently become evident, including resistance against 
miltefosine, an oral alkylphospholipid that is the most 
recently registered drug for use against VL [6,7]. This 
worrying trend has led to the use of more toxic drugs in 
the treatment of this parasitic infection. These factors 
regarding currently available treatments, combined with 
the lack of effective prophylactic vaccines against 
leishmaniasis infection, make the discovery of new 
therapeutic agents a priority; this need has also been 
recognized by the WHO [8]. 
Leishmania spp exhibit a digenetic lifecycle, alternating 
between flagellated, extracellular promastigote forms in 
the digestive tract of the sandfly vector and, following a 
bite, aflagellate intra-macrophage amastigote forms in the 
mammalian host. The changes in environment experienced 
by the parasite during the course of this lifecycle are 
dramatic, as reflected by a radical reorganization of the 
cell surface (the interface with the host). Insect-stage 
promastigote forms possess a thick glycocalyx consisting 
of glycosylphosphatidylinositol (GPI)-anchored proteins 
and glycoconjugates, the most abundant being 
lipophosphoglycan (LPG) [9], which has been demonstrated 
to play a central role in infection [10]. In contrast to the 
insect stages of Leishmania spp, intracellular amastigotes 
downregulate the expression of LPG (and other surface 
macromolecules) and lack a conspicuous surface coat; 
however, similar to promastigotes, the amastigotes 
possess a plethora of free GPI-anchored glycolipids, 
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termed glycoinositolphospholipids (GIPLs). In addition, 
Leishmania amastigotes sequester host glycolipid, which 
is then displayed on the surface of the parasite [9]. The 
mode by which this relatively minimalist glycocalyx 
protects the amastigote from the degradative action of 
host macrophages remains unclear. However, when 
investigating potential therapies for leishmaniasis, it is 
important to consider the major changes that occur during 
differentiation of the Leishmania parasites with respect 
to surface determinants, and how these changes may be 
exploited in a therapeutic context. 
Currently available therapies for 
leishmaniasis
As noted, no vaccine against Leishmania spp is currently 
available, and several issues must be addressed before 
such a vaccine can be developed successfully [11]. 
Therefore, the treatment of leishmaniasis relies entirely on 
chemotherapy. Pentavalent antimonials, such as sodium 
stibogluconate (Pentostam) and meglumine antimoniate 
(Glucantime), are the most commonly used first-line drugs 
in the treatment of both VL and CL [12,13]. These drugs 
have been in clinical use for more than 70 years, despite 
being associated with severe side effects, such as 
renal failure and cardiotoxicity [14], and the current 
requirement for intravenous administration [15]. However, 
the most urgent and concerning issue regarding the 
use of pentavalent antimonials in the treatment of 
leishmaniasis is the emergence of drug resistance [6]. 
Fortunately, such resistance has not yet been widespread, 
and remains isolated to the North Bihar region of India 
where VL is endemic [16]. This emergence of drug 
resistance has primarily been attributed to the misuse of 
these drugs, which are available freely as OTC agents in 
this region [17]. Furthermore, Leishmania spp parasite 
resistance to the pentavalent antimonials can be 
induced easily in the laboratory [18]. Combined, these 
observations have led to concerns that the antimonials 
may soon become ineffective. Second-line drugs, including 
amphotericin B (Fungizone) [19] and the aromatic 
diamidine pentamidine [20], have consequently been used 
increasingly in the treatment of both CL and VL. Both of 
these agents have been in use for more than 30 years 
and, similar to the antimonials, induce severe side effects 
[14]. A lipid formulation of amphotericin B (AmBisome) 
has also been developed [21], which demonstrates higher 
efficacy and lower toxicity compared with the original 
drug [13]. However, although the price of AmBisome in VL 
endemic, resource-limited regions has been reduced via 
a partnership between the WHO and the manufacturer 
Gilead Sciences Inc [22], the cost remains high for 
developing nations [23]. The aminoglycoside paromomycin 
(Humatin) is used as a topical, second-line therapy for 
CL, and is also used as a low-cost parenteral treatment for 
VL in India [24]. Parasite resistance towards second-line 
drugs for leishmaniasis has not been confirmed conclusively 
but there are indications, based on decreased pathogen 
susceptibility following patient relapse, that this may 
occur in the near future [25]. As a result, combination 
therapies are being evaluated; sodium stibogluconate 
plus paromomycin has been demonstrated to be effective 
against VL in clinical trials conducted in both Africa and 
India [24]. However, miltefosine, the only orally 
administered treatment available for VL, is also effective 
against CL [26,27]. Through its dual effectiveness – and 
being the only antileishmanial agent to have completed 
phase IV clinical trials – miltefosine is the most likely 
candidate to replace antimonials as the first-line drug 
treatment for leishmaniasis in the next decade [12]. 
Unfortunately, similar to the other antileishmanials, 
miltefosine is also associated with severe side effects 
[28] and, in addition, is teratogenic, thus precluding 
administration during pregnancy [29]. Furthemore, 
parasite resistance to miltefosine can emerge easily, as has 
been readily observed in vitro [30]. Data from controlled 
clinical trials revealing resistance have also suggested that 
miltefosine may only be effective as an antileishmanial 
agent for a short time period [31].
Thus, all currently used first-line and second-line drugs 
for the treatment of leishamaniasis have issues in terms 
of toxicity, cost and/or administration. Furthermore, the 
prospect of the emergence of widespread drug resistance 
indicates that there is an urgent need to develop new 
and effective therapies for leishmaniasis. This review 
summarizes research aimed at investigating the 
potential development of antimicrobial peptide-based 
antileishmanial agents.
Antileishmanial properties of antimicrobial 
peptides 
Antimicrobial peptides (AMPs) have been identified in a 
wide variety of organisms, including bacteria [32], plants 
[33], insects [33,34] and mammals [35], and the number 
of new AMPs being isolated, characterized and collated 
in databases such as AMPer [36] continues to increase 
rapidly. AMPs are produced in response to infection, and 
represent key components of the innate immune system 
[37]. They can vary both in size and structure across 
species and, in general, are cationic, although examples 
of anionic AMPs have also been reported [38]. Many AMPs 
also exhibit broad-spectrum antibacterial activity, even 
against multidrug-resistant bacterial strains, and have 
low cytotoxicity to mammalian cells. Over the past 
20 years, these attributes have precipitated considerable 
research efforts directed toward the development of 
AMP-based antibiotics [39]. In addition to displaying 
potent antibacterial properties, increasing numbers of 
AMPs have also been demonstrated to have biological 
activity against a range of therapeutic targets, such 
as cancer cells [40]. Furthermore, AMPs can possess 
antiviral [41], antifungal [42], and even spermicidal 
activity [43]. 
AMPs are also excellent candidates for the design of novel 
antiprotozoal agents; however, this possibility has not been 
fully investigated or exploited [44]. The reasons for the 
lack of research in this area can be attributed, in part, to 
the fact that many parasitic infections are most prevalent 
in developing countries, and that the development of 
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new antiparasitic agents is regarded as a relatively low 
priority by pharmaceutical companies. However, AMPs 
possess several attractive attributes as potential 
antileishmanial agents, including the lack of toxicity 
toward mammalian cells at concentrations required to kill 
Leishmania parasites. Furthermore, studies indicate that 
AMPs exert their antileishmanial activity via a disruption 
of biological membranes [39], a mechanism that is 
considerably different to those used by the currently 
available drugs. This novel mechanism of action may 
provide AMP-based antileishmanial agents with the 
ability to overcome the resistance observed with existing 
drugs, thus allowing their potential use in combination 
therapies. 
The first AMP reported to exhibit antileishmanial activity 
was a dermaseptin [45]. Since this discovery, AMPs 
isolated from a variety of sources have demonstrated 
activity against a range of Leishmania species (Table 1) 
[45-61]. The largest subgroup of AMPs to be screened 
for antileishmanial activity were isolated from amphibian 
sources. This source of peptides is not surprising, as 
many amphibian AMPs, such as temporins A and B [51], 
are relatively short and, thus, are easy to prepare and 
modify and are good candidates for drug development. 
Recently, the first examples of plant-derived AMPs to 
exhibit antileishmanial activity were reported [60]. However, 
perhaps the most interesting AMP screened against 
Leishmania spp is the Phlebotomus duboscqi defensin 
[58]. This peptide was isolated from the hemolymph 
of Leishmania major-infected P duboscqi sandflies, the 
natural vector for the transmission of leishmaniasis in the 
Old World. P duboscqi defensin exhibited an IC50 value 
of 68 to 85 µM against L major promastigotes, thus 
suggesting a potential role for this AMP within 
Leishmania-infected sandflies. The investigators speculated 
that the defensin was involved in the control of parasite 
numbers within the sandfly midgut [58]. 
The number of AMPs that have been screened against 
Leishmania spp (Table 1) is relatively small compared with 
those that have been tested for activity against bacteria 
and fungi. In addition to the economic and social reasons 
for the lack of progress in this area, technical difficulties 
associated with cultivating Leishmania parasites, 
particularly the clinically relevant amastigote forms, 
may also play a role in this difference. As shown in 
Table 1, most of the AMPs screened thus far have yet to 
be tested against amastigote forms of Leishmania. As 
discussed in the Introduction, there are considerable 
differences in plasma membrane composition between 
the amastigote and promastigote forms of the parasite [9]. 
Given that the plasma membrane is the main biological 
target of AMPs, it is likely that the activity of these 
agents will vary against each of the Leishmania lifecycle 
stages. Consequently, it is difficult to ascertain whether 
AMPs that have been screened against Leishmania 
promastigotes will demonstrate similar effects against 
amastigotes, an attribute that would render them 
candidates for further drug development. 
The mode of action of antimicrobial peptides 
In general, there are two distinct mechanisms via which 
AMPs exert their biological activity [39]. First, AMPs 
can cause the disruption of the plasma membrane of the 
target organism. This mechanism is the most commonly 
used by AMPs. Second, several AMPs can traverse the 
plasma membrane and act against intracellular targets. 
Detailed studies regarding the mode of action that 
AMPs use against various Leishmania spp have not been 
conducted exhaustively, but both of these mechanisms 
have been observed to date. For example, transmission 
electron microcopy confirmed that membrane disruption 
occurred in Leishmania promastigotes and amastigotes 
treated with temporins A and B [51]. Similar studies also 
confirmed that other AMPs, such as bombinins, acted 
via this mechanism [53]. This primary mode of action 
may provide AMP-based drugs with one major advantage 
over current treatments: for drug resistance to develop 
against such AMP-based drugs, Leishmania parasites 
would need to alter their membrane structure and/or 
phospholipid composition, and such modifications would 
be difficult to accomplish. 
Two AMPs, indolicidin [57] and histatin-5 [61], have been 
demonstrated to exert antileishmanial activity by acting 
on intracellular targets. Indolicidin had the ability not 
only to disrupt the parasite membrane, but also to induce 
autophagic cell death [57]. Histatin-5 did not cause 
severe disruption to the plasma membrane, but was 
active against both Leishmania donovani promastigotes 
and Leishmania pifanoi axenic amastigotes [61]. The 
intracellular accumulation of histatin-5 in both of these 
species was confirmed using confocal microscopy 
and labeled peptides. Further experiments indicated 
that histatin-5 targeted the mitochondrion, causing 
bioenergetic failure and leading to non-apoptotic cell death. 
Interestingly, the d-isomer of histatin-5 was more active 
against both promastigotes and amastigotes compared 
with the natural isomer, suggesting that the intracellular 
target involved in mediating antileishmanial action does 
not involve chiral recognition. The investigators proposed 
that the enhanced biological activity of the d-isomer 
resulted from resistance to proteolytic cleavage. This 
hypothesis was supported experimentally by data 
demonstrating accumulation of the d-isomer inside the 
parasite at concentrations that were higher than those of 
the natural histatin-5 [61]. 
Methods to enhance the antileishmanial 
activity of peptides
The inherent susceptibility of peptides toward chemical 
and enzymatic degradation is a major hurdle that needs 
to be overcome for the successful development of 
peptide drugs. Several different approaches, including the 
incorporation of non-proteinogenic amino acids, backbone 
cyclization and the use of encapsulating delivery strategies, 
have been developed in an effort to circumvent the 
issue of degradation [62-64]. In particular, modifications 
have been performed on AMPs with antileishmanial 
activity as part of drug development efforts. 
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In the case of the wasp-venom AMP decoralin, a simple 
amidation of the carboxy-terminus resulted in an increase 
in activity against L major promastigotes [56]. Amidation 
of the carboxy-terminus is a widely applied strategy in 
SAR studies in peptide chemistry. This modification can 
enhance stability against protease degradation, or can 
help stabilize the α-helical secondary structure that is 
required for plasma membrane disruption by many AMPs. 
The preparation of hybrid peptides derived from two 
AMPs with established antileishmanial activity has also 
been explored. A hybrid of cecropin A and melittin [CA(1-8)
M(1-18)] demonstrated a higher level of activity against 
L donovani promastigotes than cecropin A [49]. However, 
the activity of the hybrid peptide was reduced compared 
with melittin, thus rendering the significance of these 
data unclear. Additional studies have revealed that 
acylation of the hybrid peptide CA(1-7)M(2-9) with 
various fatty acid chains [C(2) to C(16)] could be used to 
enhance activity against Leishmania parasites [65]. 
Notably, activity against amastigotes with the hybrid 
peptide increased by 15-fold, suggesting that such 
a modification could be useful to apply to other 
antileishmanial AMPs. Interestingly, the acylated hybrid 
peptide Oct-CA(1-7)M(2-9) was demonstrated to be a 
safe and effective treatment for naturally acquired canine 
CL when administered by intravenous injection [66]. These 
results are encouraging, but given the restrictions and 
costs of such in vivo experiments similar proof of 
concept studies are unlikely to be conducted routinely 
with other promising AMP candidates.
Another factor that may be prohibitive in the development 
of AMP-based drugs is the high production cost involved 
compared with small-molecule drug development. 
However, this cost could be reduced by identifying the 
minimal peptide sequence that is capable of retaining 
biological activity. By screening short fragments of a 
known mussel defensin, Bernard and colleagues identified 
a cyclic peptide of only nine amino-acid residues that 
exhibited an ID50 value of 12 µM against L major 
promastigotes [67]. When adopting such an approach, it is 
important to investigate all potential cytotoxic properties 
of the peptides against mammalian cells, as a reduction 
in size is often accompanied by a reduction in membrane 
selectivity. Some SAR data have also been reported for 
the AMPs magainin 2 [68] and dermaseptin S4 [47,69], but 
these studies were performed only against promastigotes. 
Therefore, it is unclear whether the observations made 
could be used successfully to assist in the rational 
design of AMP analogs with enhanced activity against 
pathogenic Leishmania amastigotes. 
Although some interesting observations have arisen 
from these modifications, there are still no specific 
guidelines that can be used for the optimal selection 
of AMP candidates. More detailed SAR data are 
required, particularly with respect to Leishmania 
amastigotes, so that the properties and peptide motifs 
that are required for biological activity can be further 
established. 
Potential challenges to antileishmanial 
antimicrobial peptide drug development 
Two potential issues are pertinent to the future development 
of AMP-based antileishmanials. First, the surface 
metalloprotease GP63, also known as leishmanolysin, 
may protect Leishmania from AMPs. Notably, some AMPs 
tested against leishmanolysin-knockout mutants of 
L major promastigotes displayed higher levels of 
leishmanicidal activity [70]. However, it is unlikely that 
leishmanolysin activity is a significant factor in the 
resistance of different Leishmania spp toward all AMPs, as 
certain AMPs display reduced activity toward the clinically 
relevant amastigote forms of the parasite, despite the 
fact that these forms express minimal levels of 
leishmanolysin [71]. A second potential hurdle relates to 
the intracellular targeting by Leishmania parasites (which 
generally target macrophages). As a result, any AMP 
drug will need to have the ability to cross several physical 
barriers to reach the parasite, and will need to display 
little or no toxicity toward the host cell. The issue of 
toxicity is perhaps the least problematic, as several 
of the AMPs that have been screened (Table 1) have 
demonstrated low cytotoxicity toward macrophages [61]. A 
more significant challenge may relate to the identification 
of AMPs for which promising leishmanicidal activity 
against axenic extracellular parasites can be transferred 
to Leishmania-infected in vitro macrophage models. 
Currently, research investigating AMPs in macrophage 
models has been limited [51,61], although quantitative, 
but technically demanding, assays are available [72]. 
However, if AMPs are to be developed further as 
antileishmanial agents, more detailed information 
regarding the modes of action and activity of AMPs against 
Leishmania-infected macrophages will be required. 
Conclusion
The number of AMPs screened against Leishmania species 
has been steadily increasing. However, despite this 
increase, the total number of AMPs that have been tested 
against this protozoan parasite remains low compared 
with the number of AMPs that have been screened against 
bacterial species. Given this relative paucity of data, it 
remains difficult to derive general conclusions that would 
aid researchers in the rational selection and design of 
antileishmanial AMPs. In addition to the lack of SAR data, 
many of the published studies in the field have focused 
on the insect-stage, promastigote form of Leishmania 
rather than the clinically relevant intra-macrophage 
amastigote form. Given the evident difference in the 
surface architecture of these two lifecycle stages, it is 
important to screen AMPs against amastigotes as well 
as promastigotes, despite the inherent challenges. 
The mammalian stage of the Leishmania lifecycle that 
occurs within macrophages presents a hurdle to the 
development of any antileishmanial drug, including AMPs. 
In addition to concerns regarding host cytotoxicity, any 
compound would have to penetrate the phagolysosome 
within which the amastigotes persist. Few AMPs 
have been assessed for their ability to inhibit or clear 
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amastigotes from infected tissue culture macrophages or 
in animal models. However, those AMPs that have been 
tested in these systems have demonstrated encouraging 
results, and further research is therefore warranted. 
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